GMU’s Reverse-phase Protein Microarray Technology Included in I-SPY2 Breast Cancer Trial

Technology developed by Lance Liotta and Emanuel Petricoin will be used to find and identify biomarkers for evaluating new investigational therapies for the neoadjuvant-drug study.

Full-text access for premium subscribers only. Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.

Related Stories